Koutroulis Ioannis, Batabyal Rachael, McNamara Brittany, Ledda Matthew, Hoptay Claire, Freishtat Robert J
Division of Emergency Medicine, Children's National Hospital, Washington, DC.
Center for Genetic Medicine, Children's National Research Institute, Washington, DC.
Crit Care Explor. 2019 Nov 14;1(11):e0061. doi: 10.1097/CCE.0000000000000061. eCollection 2019 Nov.
This review will examine current definitions and trends in sepsis management as well pathophysiologic mechanisms in animal and ex vivo studies that correlate decreased energy production with deranged inflammatory response during the septic process.
The latest articles in the literature that focus on the role of immunometabolism and associated mechanisms in sepsis were selected.
The most relevant, original articles were included in the review.
All pertinent data for sepsis definitions as well as changes in immunometabolic pathways during the septic process was reviewed and assessed for inclusion in this article.
Sepsis is a major cause of multiple organ dysfunction. It is the principal cause of death resulting from infection and one of the most expensive conditions treated in the United States. Despite current efforts to accurately define sepsis, novel treatments and highly trained providers, mortality rates for sepsis remain high, prompting a need for further investigation of underlying immunometabolic mechanisms to identify potential treatment targets. The definition of sepsis has shifted and changed in the past few decades due to poorly defined criteria, as well as unclear guidelines for providers with regards to management of severe sepsis and septic shock. The early identification of patients with a systemic inflammatory response that will progress to septic shock is critical since recent traditional therapeutic approaches, such as early goal-directed therapy, IV immunoglobulin, and anti-tumor necrosis factor-α antibodies have failed.
There are no effective anti-sepsis drug therapies due to complex inflammatory and metabolic interactions. Further studies regarding the interface between innate immunity and metabolism should be investigated to effectively address septic patient mortality rates.
本综述将探讨脓毒症管理的当前定义和趋势,以及动物和体外研究中的病理生理机制,这些机制将脓毒症过程中能量产生减少与紊乱的炎症反应联系起来。
选择了文献中关注免疫代谢及其在脓毒症中的相关机制作用的最新文章。
最相关的原创文章被纳入综述。
对脓毒症定义以及脓毒症过程中免疫代谢途径变化的所有相关数据进行了审查和评估,以确定是否纳入本文。
脓毒症是多器官功能障碍的主要原因。它是感染导致死亡的主要原因,也是美国治疗费用最高的病症之一。尽管目前努力准确界定脓毒症,有新颖的治疗方法和训练有素的医疗人员,但脓毒症的死亡率仍然很高,这促使需要进一步研究潜在的免疫代谢机制,以确定潜在的治疗靶点。在过去几十年中,由于标准定义不明确,以及针对严重脓毒症和脓毒性休克治疗的医疗人员指南不清晰,脓毒症的定义发生了变化。早期识别有全身炎症反应且将进展为脓毒性休克的患者至关重要,因为最近的传统治疗方法,如早期目标导向治疗、静脉注射免疫球蛋白和抗肿瘤坏死因子-α抗体均已失败。
由于复杂的炎症和代谢相互作用,目前没有有效的抗脓毒症药物疗法。应进一步研究先天免疫与代谢之间的相互关系,以有效降低脓毒症患者的死亡率。